Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II
Open Access
- 24 January 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 105 (3) , 304-317
Abstract
Cardiac remodelling is one of the key pathological changes that occur with cardiovascular disease. Previous studies have demonstrated the beneficial effects of CYP2J2 expression on cardiac injury. In the present study, we investigated the effects of cardiomyocyte-specific CYP2J2 expression and EET treatment on angiotensin II-induced cardiac remodelling and sought to determine the underlying molecular mechanisms involved in this process. Eight-week-old mice with cardiomyocyte-specific CYP2J2 expression (αMHC-CYP2J2-Tr) and wild-type (WT) control mice were treated with Ang-II. Ang-II treatment of WT mice induced changes in heart morphology, cardiac hypertrophy and dysfunction, as well as collagen accumulation; however, cardiomyocyte-specific expression of CYP2J2 attenuated these effects. The cardioprotective effects observed in α-MHC-CYP2J2-Tr mice were associated with peroxisome proliferator-activated receptor (PPAR)-γ activation, reduced oxidative stress, reduced NF-κB p65 nuclear translocation, and inhibition of TGF-β1/smad pathway. The effects seen with cardiomyocyte-specific expression of CYP2J2 were partially blocked by treatment with PPAR-γ antagonist GW9662. In in vitro studies, 11,12-EET(1 μmol/L) treatment attenuated cardiomyocyte hypertrophy and remodelling-related protein (collagen I, TGF-β1, TIMP1) expression by inhibiting the oxidative stress-mediated NF-κB pathway via PPAR-γ activation. Furthermore, conditioned media from neonatal cardiomyocytes treated with 11,12-EET inhibited activation of cardiac fibroblasts and TGF-β1/smad pathway. Cardiomyocyte-specific expression of CYP2J2 or treatment with EETs protects against cardiac remodelling by attenuating oxidative stress-mediated NF-κBp65 nuclear translocation via PPAR-γ activation.Keywords
This publication has 43 references indexed in Scilit:
- Peroxisome Proliferator-Activated Receptor-γ Activation With Angiotensin II Type 1 Receptor Blockade Is Pivotal for the Prevention of Blood-Brain Barrier Impairment and Cognitive Decline in Type 2 Diabetic MiceHypertension, 2012
- Epoxyeicosatrienoic acids protect rat hearts against tumor necrosis factor-α-induced injuryJournal of Lipid Research, 2012
- Epoxyeicosatrienoic Acids Attenuate Reactive Oxygen Species Level, Mitochondrial Dysfunction, Caspase Activation, and Apoptosis in Carcinoma Cells Treated with Arsenic TrioxideThe Journal of Pharmacology and Experimental Therapeutics, 2011
- MMP-2 Mediates Angiotensin II–Induced Hypertension Under the Transcriptional Control of MMP-7 and TACEHypertension, 2011
- HIV and HCV Cooperatively Promote Hepatic Fibrogenesis via Induction of Reactive Oxygen Species and NFκBJournal of Biological Chemistry, 2011
- Overexpression of Cytochrome P450 Epoxygenases Prevents Development of Hypertension in Spontaneously Hypertensive Rats by Enhancing Atrial Natriuretic PeptideThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicityAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Requirement of Rac1 in the development of cardiac hypertrophyProceedings of the National Academy of Sciences, 2006
- Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblastsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- TIMP-1Hypertension, 2002